Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Correction to: Scientific Reports 10.1038/s41598-020-71263-9, published online 1 September 2020

In this Article, Figure 1 and its accompanying legend are incorrect. The correct Figure 1 and legend appear below.

Figure 1

A correct version of the original Figure 1. A high proportion of patients may be sensitive to PI3K/PIM inhibition. (A) Venn diagrams demonstrate the percentage of the prostate cancer cohort (TCGA or Ross-Adams, non-metastatic radical prostatectomy patients) that exhibited overexpression of the PI3K pathway, PIM pathway, or both. (B) Disease free survival probability of patients with any pathway upregulation versus no upregulation (left) and after separation into specific pathways (right). P-value was obtained using a Mantel-Cox test. (C) Distribution of Gleason grades within patient population groups. A higher Gleason score (1–5) indicates less well-differentiated prostate tissue and more aggressive disease. A Gleason grade is obtained by adding the Gleason scores of the two most prevalent tissue types in the sample. P-value was obtained using a Chi-square method, and is plotted as a proportion of the patients within each Gleason sum group that fall into each expression group (PIM positive, PI3K positive, both positive or any positive), with colours corresponding to parts A and B.